Excellent Results in a Transformational Year for Shire; Core Product Sales up 25% Earthtimes (press release) VYVANSE, our leading ADHD treatment with a current monthly US ADHD market share of 13.6%, continues to grow and build strong brand recognition in the US and ... |
Excellent Results in a Transformational Year for Shire; Core Product Sales up 25% MSN Money VYVANSE, our leading ADHD treatment with a current monthly US ADHD market share of 13.6%, continues to grow and build strong brand recognition in the US and ... |
 BNET | Facing Stunted Growth in ADHD Market, Shire Clicks on Twitter BNET Shire plc expects strong growth in sales of Vyvanse to offset any loss in market share experienced by its best selling, ... |
Shire announces third quarter 2009 financial results News-Medical.net We have also continued to grow VYVANSE's market share which is now 13.4%, benefiting from both the 'back to school' season and strong 10% ADHD market growth ... and more » |
Shire Continues to Deliver Excellent Growth From Core Products SunHerald.com (press release) We have also continued to grow VYVANSE's market share which is now 13.4%, benefiting from both the 'back to school' season and strong 10% ADHD market growth ... |